Pfizer Inc. said a final analysis of clinical-trial data showed its Covid-19 vaccine was 95% effective, paving the way for the company to apply for the first us regulatory authorization for a coronavirus shot within days.
"The safety milestone required by the US Food and Drug Administration (FDA) for EUA has been achieved".
"They are easy platforms, availability of doses is very high", he said, adding that they will control the pandemic.
But there are also important differences between the two.
Pfizer-BioNTech use the "mRNA" technology which means the vaccine is not embedded with the virus itself and there is, therefore, no risk of catching COVID-19 from the shot.
Despite recent promising announcements from final-phase candidate vaccine trials, "We're not there with vaccines yet", Mr Ryan said.
The companies' release said they plan to file for an emergency use authorization "within days" with the FDA.
In Moderna's study, there were 11 cases of severe Covid-19, all of which occurred in the placebo group.
QUIZ: The 50-year history of the ATP Finals
Tsitsipas can still advance depending on his results against Nadal and Rublev in the last two group-stage rounds. Tsitsipas broke for a 2-1 lead in the second set with a forehand passing shot before leveling the match.
However, Johnson & Johnson's vaccine had snafus of its own, including a pause in the phase 3 trial that launched in late September due to a serious medical event in one of its participants.
NITI Aayog member Dr VK Paul said that trials of five vaccines are going on in different stages in the country. Moderna then reported a week later that its vaccine was 94.5% effective.
Equity markets strengthened slightly on the Pfizer news.
Pfizer and BioNTech announced on November 9 that their mRNA-based vaccine candidate, BNT162b2, showed evidence of being more than 90% effective against COVID-19 in participants without prior evidence of the coronavirus infection.
Wednesday's news came after 170 people fell sick in an ongoing clinical trial of nearly 44,000 people - 162 of whom were in a placebo group and eight of whom received the two-dose medicine.
The final results of Pfizer's Covid-19 vaccine trial are hugely significant and if it is approved by regulators in the coming days, it could be ready to be injected by the end of the month or December 1.
It said the vaccine had proven 90 percent effective in preventing Covid-19 symptoms and did not produce adverse side effects among thousands of volunteers.
India has pre-ordered the following vaccines: Novavax's candidate, Oxford-Astrazeneca's shot, and Sputnik V Which is being developed by Russia's Gamaleya Research Institute. Pfizer's vaccines need to be stored at -70° C (-94° F), much lower than most freezers at health facilities, so the company is planning to ship vials in special thermal containers that can maintain such ultra-cold temperatures for up to 15 days with dry ice.
Pfizer and German pharmaceutical company BioNTech are working together to produce up to 50 million vaccine doses globally in 2020, and up to 1.3 billion doses in 2021. The vaccinationrequires two shots a few weeks apart, so that would mean about 20 million people could get protection - a major step forward, though a sliver of the U.S. population.